Presentation to highlight baseline characteristics of Spruce’s CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia (CAH)

The company is also highlighting baseline characteristics from its CAHmelia program evaluating tildacerfont in adult CAH in a poster presentation

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that an accepted abstract highlighting baseline characteristics from the company’s CAHptain Phase 2 study evaluating tildacerfont in children and adolescents with congenital adrenal hyperplasia (CAH) will be presented at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.

In addition, a submitted abstract highlighting baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult CAH, as an illustration of outcomes of current pediatric CAH disease management, was accepted for poster presentation at the PES conference.

PES 2024 Poster Presentation Details:

Title: Baseline Characteristics of CAHptain: A Phase 2 Dose-finding Study of Tildacerfont in Children with Classic Congenital Adrenal Hyperplasia Abstract Number: 6899 Poster Session: 2 Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT Presenter: Mimi S. Kim, M.D., Co-Director, Congenital Adrenal Hyperplasia Comprehensive Care Clinic, Children’s Hospital Los Angeles

Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia Abstract Number: 6898 Poster Session: 2 Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT Presenter: Paul Thornton, M.B.B.S., Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence

The poster presentations will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.

Media Contact Katie Beach Oltsik Inizio Evoke Comms (937) 232-4889 Katherine.Beach@inizioevoke.com media@sprucebio.com Investors Samir Gharib President and CFO Spruce Biosciences, Inc. investors@sprucebio.com

Grafico Azioni Spruce Biosciences (NASDAQ:SPRB)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Spruce Biosciences
Grafico Azioni Spruce Biosciences (NASDAQ:SPRB)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Spruce Biosciences